{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:43Z","timestamp":1794047383189,"version":"4.8.0"},"reference-count":12,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"2","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2021.279101","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T14:51:23Z","timestamp":1623941483000},"page":"353-354","source":"Crossref","is-referenced-by-count":1,"title":["Too much and not enough: revisiting maintenance rituximab in indolent lymphomas"],"prefix":"10.3324","volume":"107","author":[{"given":"Sonali","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2021,6,17]]},"reference":[{"key":"33251","doi-asserted-by":"crossref","unstructured":"Berinstein NL, Grillo-Lopez AJ, White CA. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998; 9(9):995-1001.","DOI":"10.1023\/A:1008416911099"},{"key":"33252","doi-asserted-by":"crossref","unstructured":"Gordan LN, Grow WB, Pusateri A, Douglas V, Mendenhall NP, Lynch JW. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol. 2005; 23(6):1096-1102.","DOI":"10.1200\/JCO.2005.12.171"},{"key":"33253","doi-asserted-by":"crossref","unstructured":"Nabhan C, Ollberding NJ, Villines D. A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas. Leuk Lymphoma. 2014; 55(6):1288-1294.","DOI":"10.3109\/10428194.2013.839787"},{"key":"33254","doi-asserted-by":"crossref","unstructured":"Salles G, Seymour JF, Offner F. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011; 377(9759):42-51.","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"33255","doi-asserted-by":"crossref","unstructured":"Vidal L, Gafter-Gvili A, Salles G. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2011; 103(23):1799-1806.","DOI":"10.1093\/jnci\/djr418"},{"key":"33256","doi-asserted-by":"crossref","unstructured":"Rule S, Barreto W, Briones J. Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study. Haematologica. 2021; 107(2):500-509.","DOI":"10.3324\/haematol.2020.274803"},{"key":"33257","doi-asserted-by":"crossref","unstructured":"Taverna C, Martinelli G, Hitz F. Rituximab maintenance for a maximum of 5 years after single-agent rituximab induction in follicular lymphoma: results of the randomized controlled phase III trial SAKK 35\/03. J Clin Oncol. 2016; 34(5):495-500.","DOI":"10.1200\/JCO.2015.61.3968"},{"key":"33258","doi-asserted-by":"crossref","unstructured":"Kahl BS, Hong F, Williams ME. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol E4402. J Clin Oncol. 2014; 32(28):3096-3102.","DOI":"10.1200\/JCO.2014.56.5853"},{"key":"33259","doi-asserted-by":"crossref","unstructured":"Hiddemann W, Barbui AM, Canales MA. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018; 36(23):2395-2404.","DOI":"10.1200\/JCO.2017.76.8960"},{"key":"33260","doi-asserted-by":"crossref","unstructured":"Mato AR, Roeker LE, Lamanna N. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020; 136(10):1134-1143.","DOI":"10.1182\/blood.2020006965"},{"key":"33261","doi-asserted-by":"crossref","unstructured":"Herishanu Y, Avivi I, Aharon A. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021; 137(23):3165-3173.","DOI":"10.1182\/blood.2021011568"},{"key":"33262","unstructured":"Proceedings of the COVID-19 Vaccine Panel: a Lymphoma Research Foundation White Paper. 2021."}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.279101\/73444","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.279101\/74069","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10302\/73444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:59:47Z","timestamp":1794045587000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.279101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":12,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.279101","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,17]]}}}